A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)

NCT06953583 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

255

Enrollment

INDUSTRY

Sponsor class

Conditions

Friedreich Ataxia

Interventions

DRUG: Omaveloxolone
DRUG: Placebo

Sponsor

Biogen